Latest:
Dr Mascarenhas on Key Considerations for Clinical Trial Enrollment in Myelofibrosis
John O. Mascarenhas, MD, discusses important factors to consider when evaluating patients for clinical trial enrollment in myelofibrosis.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
John Minna, MD
Latest:
Dr. Minna on Chemotherapy and Radiation Therapy for Lung Cancer
John Minna, MD, Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology, Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research, Hamon Center for Therapeutic Oncology, Internal Medicine, Pharmacology, UT Southwestern Medical Center, discusses the roles that both chemotherapy and radiation therapy will continue to have in the treatment of lung cancer.
John Morris, MD
Latest:
Dr. Morris on Lymphopenia as a Predictor of Survival in CRT-Treated NSCLC
John Morris, MD, professor of Medicine, co-director, Comprehensive Lung Cancer Center, associate director, UCCI Translational Research and Director, Experimental Therapeutics, University of Cincinnatti, discusses lymphopenia as a predictor of survival in chemoradiation-treated non–small cell lung cancer.
John O. Mascarenhas, MD
John O. Mascarenhas, MD, is a professor of medicine at the Icahn School of Medicine at Mount Sinai; as well as director of the Center of Excellence for Blood Cancers and Myeloid Disorders, director of the Adult Leukemia Program, and a member of The Tisch Cancer Institute
Latest:
Dr Mascarenhas on the Role of Imetelstat in the Myelofibrosis Treatment Paradigm
John O. Mascarenhas, MD, discusses the potential role of imetelstat in the treatment of patients with myelofibrosis.
John Otrompke
Latest:
Second-Line Therapies for mCRPC Complicated by Drug Interactions and Dosing Issues
Approximately 4 years after the FDA approval of 2 powerful new oral androgen-targeting agents for metastatic castration-resistant prostate cancer, an analysis raised issues complicating treatment with the 2 drugs, as well as what oncologists do not yet know.
John R. Horn, PharmD, FCCP
Latest:
Drug Interactions With Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors (TKIs) are indicated for the treatment of a variety of malignancies, due to their ability to interfere with cell communication and growth. This review focuses on interactions that affect TKI metabolism.